THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU) NO.596/2014, WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"), AS AMENDED.

15 June 2023

Belluscura plc 

("Belluscura", the "Company" or the "Group") 

Confirmation of share allotment; Director / PDMR Shareholding; board appointment

Confirmation of share allotment

Further to the RNS announcement titled "Result of General Meeting" published at 12:28pm on 14 June 2023 Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that 12,386,240 new Ordinary Shares have today been allotted under the Placing, Subscription and Retail Offer.

On 25 May 2023, Belluscura announced that pursuant to a Placing and Subscription it has conditionally raised £3.0 million (approximately £2.7 million net of expenses) through the issue of 12,000,000 New Ordinary Shares at the Issue Price of 25 pence per share. The Placing and Subscription have been subscribed for by both new and existing investors.

On 1 June 2023, Belluscura announced that pursuant to a Retail Offer to its existing retail shareholders via the BookBuild Platform (the "Retail Offer"), it has conditionally raised c£0.1 million (before expenses) through the issue of 386,240 New Ordinary Shares at the Issue Price of 25 pence per share.

The Placing, Subscription and Retail Offer Shares are expected to be admitted to trading on AIM at 8:00 a.m. on or around 16 June 2023.

Following Admission, the number of Ordinary Shares in issue and the number of voting rights will be 135,670,067. The figure of 135,670,067 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Board appointment

Further to the RNS announcement titled "Board Appointment" published on 26 May 2023, Bob Fary has been appointed as an executive director with effect from 14 June 2023.

Director / PDMR Shareholding

As previously notified on 25 May 2023 the Subscribing Directors and Robert Fary have subscribed for 1,992,000 Subscription Shares at the Issue Price of 25 pence, to raise (in aggregate) gross proceeds of £498,000 (before expenses). Details of individual subscriptions are set out in the tables below.

Capitalised terms used but not defined herein shall have the same meanings given to them in the announcement of the Proposed Placing and Subscription and Retail Offer Announcements published by the Company on 25 May 2023.

For further information please contact:

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.